online ISSN 2415-3176
print ISSN 1609-6371
logoExperimental and Clinical Physiology and Biochemistry
  • 7 of 9
Up
ECPB 2020, 89(1): 50–57
https://doi.org/10.25040/ecpb2020.01.050
Research articles

The physiological and microbiological characteristics of bronchopulmonary and intestinal tracts in children with cystic fibrosis

L.M. BUROVA1, O.P KORNIJCHUK1, Y.D.MAZEPA2
Abstract

An important component of therapeutic measures for mucoviscidose is the determination of the functional state of the respiratory system, the fight against an opportunistic infection which accompanies the course of the chronic microbial-inflammatory process in the bronchopulmonary tract. Under conditions of reduced resistance to the child’s body, extra infecting of the digestive canal through the ingestion of sputum is extremely undesirable. The monitoring of the status of the microbiota of the oropharynx, the respiratory tract and the intestinal tract allows preventing the further development of the infectious process.

The aim of the present study was to determine the functional state of the respiratory and digestive systems in children with mucoviscidose against the background of quantitative changes and changes of species composition of the microbiota of the bronchopulmonary tract and intestines under the condition of the possible contamination of the gut with BPT microbiota. During the research the microbiological status of the bronchopulmonary tract was examined in 19 sick children. Faeces had been taken in 31 children, 12 of them were healthy (the control group).

In 11 patients (57,9 %) some developmental delays were observed, namely a decrease in the body weight and height. In each age group an increase in respiratory rate and a decrease in body mass index were registered. The decreased oxygen saturation was present in children from 3 to 11 years. The microflora of the bronchopulmonary tract by species was presented by isolates: S.aureus, P.aeruginosa, P.fluorescens, S.pyogenes, S.viridans, S.agalactiae, Еterterococcus spp., Neisseria spp., S.pseudodiphtheriae, S. freundii, E. coli, fungi of the Candida spp., Lactobacillus spp. Frequency of isolation of S. aureus, Pseudomonas spp. amounted to 53% and 47 % respectively.

The investigation of microbiocenosis of colon showed a moderate decrease in the number of Вifidobacteria and Lactobacilli. The reduced number of Enterococci was found in 1 patient (5,3 %), some increase in 8 patients (42,1 %). The growth in the number of Staphylococcus was observed in 3 patients (15,8 %). The quantitative level of Escherichia was reduced by 9 (47,4 %). In one patient some mold was found, in 9 patients (47,4 %) – fungi of the genus Candida. In 2 patients (10,5 %) Escherichia with atypical properties was found. Hemolytic E. coli were detected in one of the patients. The pathogenic enterobacteria and staphylococcus were not detected in the feces of any patient. 4 patients (21 %) were isolated because of S. coseri, C. freundii and K.pneumonia. In 2 patients (10,5 %) from the group “first diagnosed mucoviscidose” the state of the intestinal microflora was almost within the normal range. In 17 patient (89,5 %) postmedical dysbiosis was indicated. According to the results of microbiological studies, the endogenous colonization of the intestines of patients with mucoviscidose sputum has not been confirmed. One hundred percent of patients had steatorrhea; two patients had steatorrhea combined with creatorrhea.

Recieved: 18.02.2020

Keywords: mucoviscidose, microbial-inflammatory process, sputum, intestinal contamination

Full text: PDF (Ukr) 333K

References
  1. 1. Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy khvorym na mukovistsydoz [Elektronnyi resurs] / zatverdzheno nakazom MOZ Ukrainy vid 15.07.2016 r. No 723. - Rezhym dostupu [in Ukrainian].
  2. 2. Clinical Guidelines: Care of Children with Cystic Fibrosis. Royal Brompton Hospital [Electronic resource]/ S. Alexander [et al.]; Endorsed by the Medicines Management Board of Royal Brompton & Harefield NHS Foundation Trust, 2014. - 6th edition.
  3. 3. Berezenko VS, Reznikov YuP, Krat VV. Mukovistsydoz u ditei. Svoiechasna diahnostyka yak vazhlyvyi predyktor efektyvnosti likuvannia (klinichnyi vypadok). Perynatolohiia i pediatriia. 2017;3(71):74-80). [in Ukrainian]. doi.org/10.15574/PP.2017.71.74
  4. 4. Mazloomi Nobandegani N, Mahmoudi S, Pourakbari B, Hosseinpour Sadeghi R, Najafi Sani M, Farahmand F, Motamed F, Nabavizadeh Rafsanjani R, Mamishi S. Antimicrobial susceptibility of microorganisms isolated from sputum culture of patients with cystic fibrosis: Methicillin-resistant Staphylococcus aureus as a serious concern. Microb Pathog. 2016;100:201-4. doi.org/10.1016/j.micpath.2016.09.015
  5. 5. Klimenko VA, Yanovskaya EA, Pasichnik EV. Mikrobiocenoz respiratornogo trakta detej s mukoviscidozom v Harkovskom regione. Sovremennaya pediatriya. 2016;6(78):24-6). [in Ukrainian]. doi.org/10.15574/SP.2016.78.24
  6. 6. Reznichenko YuH, Okul TI, Maliuha VH, Stelmakh OV, Volkova IH, Petrenko LA, Karpenko VV. Pokrashchennia efektyvnosti likuvannia ditei, khvorykh na mukovistsydoz, shliakhom vkliuchennia do standartnoi terapii preparatu pulmozym. Zdorove rebёnka. 2015;62:28-31. [in Ukrainian].
  7. 7. Ostashko SI, Tereshchenko AV, Antypkin YuH ta in. Unifikovanyi klinichnyi protokol medychnoi dopomohy ditiam iz mukovistsydozom. Эlektron. zhurn. Sovremennaia pedyatryia. 2014;4:116-8. [in Ukrainian].
  8. 8. Burova LM, Burova YeD. Antybiotykochutlyvist klinichnykh izoliativ PSEUDOMONAS AERUGINOSA.Infektsiini khvoroby. 2016;3:74-7. [in Ukrainian].
  9. 9. Wang W, Yu J, He Y. et al. Ambroxol inhibits mucoid conversion of Pseudomonas aeruginosa and contributes to the bactericidal activity of ciprofloxacin against mucoid P. aeruginosa biofilms.APMIS. 2016;7(124):611-8. doi.org/10.1111/apm.12542
  10. 10. Robinson KA, Odelola OA, Saldanha IJ. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.Cochrane Database Syst Rev. 2016 Jul 20. doi.org/10.1002/14651858.CD007743.pub6
  11. 11. Fesenko MIe, Pokhylko VI, Shcherban OA ta in. Dva vypadky zakhvoriuvannia ditei na mukovistsydoz u simi. Sovremennaia pedyatryia. 2016; 6(78):120-2). [in Ukrainian]. doi.org/10.15574/SP.2016.78.120
  12. 12. Hoppe JE, Towler E, Wagner BD et al.. Sputum induction improves detection of pathogens in children with cystis fibrosis. Pediatr Pulmonol. 2015; 7(50):638-46. doi.org/10.1002/ppul.23150
  13. 13. MOZ Ukrainy Holovne sanitarno-epidemiolohichne upravliannia. Derzhavni sanitarni pravyla ta normy, hihiienichni normatyvy. 9.Epidemiolohiia. 9.5. Stan zdorovia naselennia u zviazku z vplyvom mikrobiolohichnoho faktora «Pravyla vlashtuvannia i bezpeky roboty v laboratorii mikrobiolohichnoho profilia» Derzhavni sanitarni pravyla DSP 9.9.5.-080-02 Kyiv, 2002r. [in Ukrainian].
  14. 14. Klinicheskaya laboratornaya analitika. Pod red. V.V.Menshikova. - M.: Agat- Med, 2003;(IV):815 s. [in Rossiya].


Програмування - Roman.im